SG11201505952WA - Quinoline and quinazoline amides as modulators of sodium channels - Google Patents

Quinoline and quinazoline amides as modulators of sodium channels

Info

Publication number
SG11201505952WA
SG11201505952WA SG11201505952WA SG11201505952WA SG11201505952WA SG 11201505952W A SG11201505952W A SG 11201505952WA SG 11201505952W A SG11201505952W A SG 11201505952WA SG 11201505952W A SG11201505952W A SG 11201505952WA SG 11201505952W A SG11201505952W A SG 11201505952WA
Authority
SG
Singapore
Prior art keywords
quinazoline
quinoline
modulators
amides
sodium channels
Prior art date
Application number
SG11201505952WA
Inventor
Sara Sabina Hadida-Ruah
Corey Anderson
Vijayalaksmi Arumugam
Iuliana Luci Asgian
Brian Richard Bear
Andreas P Termin
James Philip Johnson
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SG11201505952WA publication Critical patent/SG11201505952WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
SG11201505952WA 2013-01-31 2014-01-29 Quinoline and quinazoline amides as modulators of sodium channels SG11201505952WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759300P 2013-01-31 2013-01-31
PCT/US2014/013662 WO2014120815A1 (en) 2013-01-31 2014-01-29 Quinoline and quinazoline amides as modulators of sodium channels

Publications (1)

Publication Number Publication Date
SG11201505952WA true SG11201505952WA (en) 2015-08-28

Family

ID=50073532

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505952WA SG11201505952WA (en) 2013-01-31 2014-01-29 Quinoline and quinazoline amides as modulators of sodium channels

Country Status (20)

Country Link
US (2) US9139529B2 (en)
EP (1) EP2951168B1 (en)
JP (1) JP6362623B2 (en)
KR (1) KR102226587B1 (en)
CN (1) CN105073738B (en)
AR (1) AR095192A1 (en)
AU (1) AU2014212426B8 (en)
BR (1) BR112015017997B1 (en)
CA (1) CA2898650C (en)
ES (1) ES2620379T3 (en)
HK (1) HK1217691A1 (en)
HU (1) HUE032169T2 (en)
IL (1) IL240091B (en)
MX (1) MX368833B (en)
NZ (1) NZ710111A (en)
RU (1) RU2683788C2 (en)
SG (1) SG11201505952WA (en)
TW (1) TWI631105B (en)
WO (1) WO2014120815A1 (en)
ZA (1) ZA201505326B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI631105B (en) 2013-01-31 2018-08-01 維泰克斯製藥公司 Quinoline and quinoxaline amides as modulators of sodium channels
CN105026373B (en) 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 Pyridine keto-amide as sodium channel modulators
UA119147C2 (en) 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Sulfonamides as modulators of sodium channels
DK3080134T3 (en) 2013-12-13 2018-10-22 Vertex Pharma PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS
MX2016010056A (en) 2014-02-06 2016-11-15 Abbvie Inc 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof.
CA3063901A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JOP20200001A1 (en) 2017-07-11 2022-10-30 Vertex Pharma Carboxamides as modulators of sodium channels
CN111918650A (en) 2018-02-12 2020-11-10 沃泰克斯药物股份有限公司 Method of treating pain
US20220227732A1 (en) * 2018-07-09 2022-07-21 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
CN108997230B (en) * 2018-07-26 2020-08-04 山东大学 Quinoxaline derivative with matrix metalloproteinase inhibitory activity, preparation method and application thereof
US20210387966A1 (en) 2018-11-02 2021-12-16 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
CN113473987A (en) 2018-12-19 2021-10-01 细胞基因公司 Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same
CA3124130A1 (en) 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
JP2022538588A (en) * 2019-06-27 2022-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 2,3-dihydroquinazoline compounds as NaV1.8 inhibitors
CN110698418B (en) * 2019-09-11 2022-07-01 广西师范大学 3-arylamino quinoxaline-2-formamide derivative and preparation method and application thereof
CN112479996B (en) * 2019-09-12 2023-05-26 上海济煜医药科技有限公司 Pyridine nitroxide compound and preparation method and application thereof
IL293592A (en) 2019-12-06 2022-08-01 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
CN114437062A (en) * 2020-04-30 2022-05-06 成都海博为药业有限公司 Compound capable of being used as sodium channel regulator and application thereof
EP4168393A1 (en) 2020-06-17 2023-04-26 Merck Sharp & Dohme LLC 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
CN112225695B (en) * 2020-12-15 2021-03-02 上海济煜医药科技有限公司 Oxynitride and preparation method and application thereof
AR124380A1 (en) * 2020-12-18 2023-03-22 Glaxosmithkline Ip Dev Ltd CHEMICAL COMPOUNDS
IL308215A (en) 2021-05-07 2024-01-01 Merck Sharp & Dohme Llc Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2022256679A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
IL308954A (en) 2021-06-04 2024-01-01 Vertex Pharma Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
AR126669A1 (en) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A N-ACYLYDRAZONIC COMPOUNDS INHIBITORS OF Nav 1.7 AND/OR Nav 1.8, THEIR OBTAINING PROCESSES, COMPOSITIONS, USES, TREATMENT METHODS OF THESE AND KITS
AR126670A1 (en) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A N-ACYLYDRAZONIC COMPOUNDS INHIBITORS OF Nav 1.7 AND/OR Nav 1.8, THEIR OBTAINING PROCESSES, COMPOSITIONS, USES, TREATMENT METHODS OF THESE AND KITS
WO2023138599A1 (en) * 2022-01-18 2023-07-27 成都康弘药业集团股份有限公司 Aromatic fused ring nav1.8 inhibitor, and use thereof
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (en) * 1976-02-11 1977-09-09 Roussel Uclaf NEW DERIVATIVES OF 3-QUINOLEINE CARBOXYLIC ACID, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS A MEDICINAL PRODUCT
FR2377400A2 (en) * 1977-01-18 1978-08-11 Roussel Uclaf Analgesic hydroxy:quinoline carboxamide cpds. - esp. N-(2-thiazolyl)-carboxamide cpds. with 8-tri:fluoro:methyl substit.
DE3210063A1 (en) 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt SULFONYL UREAS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE
FR2530633A1 (en) * 1982-06-03 1984-01-27 Roussel Uclaf NOVEL SUBSTITUTED 2-SUBSTITUTED 4-HYDROXY 3-QUINOLINE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, THEIR USE AS A MEDICINAL PRODUCT, AND THE COMPOSITIONS COMPRISING THE SAME
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
CN1018837B (en) 1991-03-12 1992-10-28 淄博齐新塑料厂 Modified polypropylene used for making internal drum of washer and preparing process thereof
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU738037B2 (en) * 1997-04-04 2001-09-06 Pfizer Products Inc. Nicotinamide derivatives
RU2220960C2 (en) * 1997-12-22 2004-01-10 Фармация Энд Апджон Компани 4-hydroxy-3-quinolinecarboxamides and hydrazides, pharmaceutical composition and treatment method based on thereof
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
JP4056081B1 (en) 2004-07-23 2008-03-05 ファイザー・インク Pyridine derivatives
CN101466665B (en) 2006-04-11 2013-12-04 沃泰克斯药物股份有限公司 Compositions useful as inhibitors of voltage-gated sodium channels
PT2137186E (en) * 2007-03-23 2016-03-30 Amgen Inc Heterocyclic compounds and their uses
SA08290245B1 (en) * 2007-04-23 2012-02-12 استرازينيكا ايه بي Novel n- (8-Heteroaryltetrahydronaphtalene-2-Y1) or N- (5- Heteroarylchromane-3-Y1) Carboxamide Derivatives for the Treatment of Pain
BRPI0810202A2 (en) 2007-05-03 2014-10-21 Pfizer Ltd PYRIDINE DERIVATIVES
AU2008310663A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
US8389734B2 (en) 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
CA2701946A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
WO2010053757A1 (en) * 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010056865A1 (en) * 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
TWI461197B (en) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
CA2812526A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
CA2801032A1 (en) * 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
AU2012212196B2 (en) 2011-02-02 2016-10-13 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
CA2829803A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
CN105026373B (en) 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 Pyridine keto-amide as sodium channel modulators
TWI631105B (en) * 2013-01-31 2018-08-01 維泰克斯製藥公司 Quinoline and quinoxaline amides as modulators of sodium channels
KR102226588B1 (en) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 Amides as modulators of sodium channels
UA119147C2 (en) 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Sulfonamides as modulators of sodium channels
DK3080134T3 (en) 2013-12-13 2018-10-22 Vertex Pharma PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS

Also Published As

Publication number Publication date
MX2015009592A (en) 2015-11-25
KR102226587B1 (en) 2021-03-11
US20140228371A1 (en) 2014-08-14
US9783501B2 (en) 2017-10-10
BR112015017997B1 (en) 2023-03-07
CN105073738A (en) 2015-11-18
CN105073738B (en) 2018-01-05
MX368833B (en) 2019-10-18
AU2014212426B2 (en) 2018-04-26
US9139529B2 (en) 2015-09-22
HK1217691A1 (en) 2017-01-20
TW201443022A (en) 2014-11-16
IL240091A0 (en) 2015-09-24
RU2683788C2 (en) 2019-04-02
JP6362623B2 (en) 2018-07-25
BR112015017997A2 (en) 2017-07-11
BR112015017997A8 (en) 2019-11-05
AU2014212426B8 (en) 2018-05-10
TWI631105B (en) 2018-08-01
WO2014120815A1 (en) 2014-08-07
CA2898650C (en) 2021-09-07
AU2014212426A1 (en) 2015-08-06
HUE032169T2 (en) 2017-09-28
EP2951168B1 (en) 2017-01-04
RU2015136770A (en) 2017-03-07
IL240091B (en) 2019-03-31
JP2016506964A (en) 2016-03-07
CA2898650A1 (en) 2014-08-07
AR095192A1 (en) 2015-09-30
ES2620379T3 (en) 2017-06-28
NZ710111A (en) 2020-08-28
US20150336945A1 (en) 2015-11-26
EP2951168A1 (en) 2015-12-09
ZA201505326B (en) 2017-11-29
WO2014120815A9 (en) 2015-06-25
KR20150114536A (en) 2015-10-12

Similar Documents

Publication Publication Date Title
HK1217691A1 (en) Quinoline and quinazoline amides as modulators of sodium channels
HK1244269A1 (en) Pyridone amides as modulators of sodium channels
HK1217692A1 (en) Amides as modulators of sodium channels
HK1248596A1 (en) Novel sez6 modulators and methods of use
IL245733A0 (en) Aplnr modulators and uses thereof
LT3043785T (en) Application of r-ketamine and salt thereof as pharmaceuticals
EP2967833A4 (en) Aligned fiber and method of use thereof
EP2973202A4 (en) Display privacy with dynamic configuration
HK1221416A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
IL244930A0 (en) Quinolinyl modulators of ror gamma t
RS58834B1 (en) Micropeptides and use of same for modulating gene expression
HK1224307A1 (en) Protoxin-ii variants and methods of use -ii
SG11201507389RA (en) Integration of hydro-dechlorination and hydro-regeneration
GB201307521D0 (en) Securing and driving of connector elements
SG11201507843TA (en) Piperaquine microcapsules and compositions containing them
EP2972573A4 (en) Variable-emittance electrochromic devices and methods of preparing the same
HK1207589A1 (en) Polymorphic forms of icotinib phosphate and uses thereof
ZA201508950B (en) New polymorphic forms of icotinib phosphate and uses thereof